Alto Neuroscience

Alto Neuroscience is a precision psychiatry company based in Los Altos, California, developing AI-driven tools to match patients with the psychiatric treatments most likely to work for their individual neurobiology. At the core of their platform is EEG-based biomarker technology that captures neural signatures unique to each patient, enabling clinicians to move away from the conventional trial-and-error approach to antidepressant prescribing. By combining neurophysiological data with machine learning, Alto's platform can predict a patient's likely response to a given treatment before therapy even begins. This positions the company as a direct response to one of psychiatry's most persistent clinical challenges: the fact that fewer than half of patients respond to their first antidepressant prescription.

Alto Neuroscience has raised $60 million in Series B funding, reflecting strong investor confidence in both the scientific validity and commercial potential of their approach. The company has made meaningful clinical progress, demonstrating in research settings that their neural signature methodology can reliably forecast antidepressant outcomes prior to treatment initiation. These milestones signal a maturing pipeline and suggest the platform is advancing toward broader clinical validation and, ultimately, real-world deployment. Their work builds on a growing body of neuroscience research linking quantitative EEG measures to psychiatric drug response, lending scientific credibility to their commercial ambitions.

Alto Neuroscience represents a meaningful inflection point for the broader neurotech and mental health technology industries, offering a data-driven alternative to the largely subjective diagnostic frameworks that have historically governed psychiatric care. Their work demonstrates that objective, brain-based biomarkers can be translated into actionable clinical tools at scale, a proof of concept with implications well beyond depression treatment. As the mental health crisis continues to strain healthcare systems globally, the ability to reduce failed treatment cycles has significant consequences for patient outcomes, healthcare costs, and clinician efficiency. Alto's platform is a compelling example of how neurotechnology can move from laboratory science into practical clinical infrastructure, helping to define what the next generation of psychiatric care could look like.